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Abstract
Introduction: The demographics of aging of the surgical population has
increased the risk for perioperative neurocognitive disorders in which
trauma-induced neuroinﬂammation plays a pivotal role.
Sources of data: After determining the scope of the review, the authors
used PubMed with select phrases encompassing the words in the scope.
Both preclinical and clinical reports were considered.
Areas of agreement: Neuroinﬂammation is a sine qua non for development
of perioperative neurocognitive disorders.
Areas of controversy: What is the best method for ameliorating trauma-
induced neuroinﬂammation while preserving inﬂammation-based wound
healing.
Growing points: This review considers how to prepare for and manage the
vulnerable elderly surgical patient through the entire spectrum, from pre-
operative assessment to postoperative period.
Areas timely for developing research:What are the most effective and safest
interventions for preventing and/or reversing Perioperative Neurocognitive
Disorders.
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Introduction to perioperative
neurocognitive disorders (PND)
The clinical problem
The aging of surgical patients as well as the increase
in surgical volume, which will soon reach a quarter
of a billion procedures,1 have converged to provide
the ‘perfect storm’ regarding the frequency of PND
and the resulting increase in mortality and early
retirement from the workforce.2 Postoperative
Delirium (POD) is the most common surgical com-
plication among older surgical patients, occurring
in between 15% and 25% following major elective
surgery and considerably higher in susceptible
patients undergoing hip-fracture repair and cardiac
surgery.3 The healthcare costs associated with these
conditions are staggering; for example, a bout of
POD can raise the in-hospital costs by between
$16 000 and 64 000.4
Nomenclature
A plethora of non-standardized terms has been used
to describe the spectrum of postoperative deterior-
ation in cognitive performance that can differ
according to time of onset, duration, severity, and
the cognitive domains that are affected. The
International Perioperative Cognition Nomenclature
Working Group,5 with expertize in postoperative
medicine, cognitive neurosciences and epidemiology,
coined the term Perioperative Neurocognitive Disorders
(PND) that is both over-arching and aligned to the
most recent Diagnostic and Statistical Manual of
Mental Disorders (DSM V). Notwithstanding that
the new semantic classiﬁcation has yet to be ratiﬁed
by the relevant medical societies, in this review we
will use the encompassing term PND as the manu-
script describing the new nomenclature has been
published in the major journals in Anesthesiology
(British Journal of Anaesthesia, Anesthesiology,
Anesthesia and Analgesia, Acta Anaesthesiologica
Scandinavica, Canadian Journal of Anaesthesia).
Thus, PND denotes all the postoperative cognitive dis-
orders including POD to reﬂect an acute onset and
ﬂuctuating course of inattentiveness, level of con-
sciousness, and disordered thinking and, Postoperative
Cognitive Dysfunction (POCD) to depict a longer-
lasting decline in cognitive function from the preopera-
tive status. As the diagnosis of POCD requires a
deterioration from an established baseline, this condi-
tion is more established in the research domain
because assessment of cognitive function is not yet a
standard part of preoperative clinical management.
Pathophysiologic mechanisms
Apart from the requirement of a surgical procedure
several other clinical circumstances have been pro-
posed, and rejected, as pivotal requirements for the
pathophysiology of PND; among the rejected clin-
ical circumstances for the development of PND,
include the type of anesthetic procedure (general vs.
regional), as well as intra-operative physiological
perturbations (especially, hypotension and hypox-
emia).6 Consideration of the putative mechanisms
must explain the age-dependency, the increased risk
in patients with metabolic syndrome patients, and
in patients in whom an inter-current infection
develops.
Supporting evidence for the
neuroinﬂammatory basis of PND
Before describing the likely sequence of events that
constitute the neuroinﬂammatory basis for PND, it
is worth considering the systems, cell types and bio-
chemical entities that are involved from surgical
incision until cognitive decline.
Systems
The Immune System comprises the Adaptive and
Innate arms with the latter dominating in the devel-
opment of PND. Apart from the barrier functions
provided by skin and mucosa, the Innate Immune
System consists of cellular and chemical constitu-
ents that are the key elements to inﬂammation.
The blood–brain barrier (BBB) consists of both
cellular and membranous components that form
tight junctions thereby protecting the brain from
the harmful effects of toxins and other detrimental
products in the peripheral circulation.
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Neuroplasticity is the basis for changing brain
function whether it be for the better, e.g. learning
and memory, or the worse, e.g. chronic pain. The
key elements are the synaptic junction that includes
both the presynaptic and postsynaptic neurones, the
neurotransmitters that are released presynaptically
and the postsynaptic signaling pathways that trans-
duce the effect of the neurotransmitters.
Cells
Circulating in the peripheral blood are monocytes
that are derived from haematopoietic sources such
as the bone marrow; when these bone marrow-
derived monocytes (BM-DMs) leave the circulation
they assume the tissue macrophage phenotype that
can be either pro-inﬂammatory (M1) or pro-
resolving (M2).7
In the parenchyma of the brain are located the
microglia, resident macrophages that had reached
its destination during embryologic development
before formation of the BBB. Microglia continu-
ously survey the milieu responding to changes by
adopting an M1 or M2 phenotype.
Damage-associated molecular patterns
(DAMPs), cytokines and chemokines
These organic molecules are the originators, media-
tors and chemo-attractants that are required for the
fully-ﬂedged inﬂammatory response.
Lipoxins, resolvins, protectins and
maresins
These are specialized pro-resolving mediators
(SPMs) that are biotransformation products of
polyunsaturated fatty acids and are required for the
successful resolution of inﬂammation.
Proposed sequence of changes (Fig. 1)
The damage-associated molecular pattern (DAMP),
known as high molecular group Box 1 protein
(HMGB1), is released from the cytosolic compart-
ment of traumatized tissue and engages the innate
immune system by binding to pattern recognition
receptors on BM-DMs to induce translocation of
the transcription factor NFκB into the nucleus
where it enhances the transcription and translation
of pro-inﬂammatory cytokines.8–10 The released
cytokines are capable of disrupting the BBB, allow-
ing the migration of both cells and potential neuro-
toxins, such as ﬁbrinogen,11 into the CNS.
Translocation of BM-DMs into the brain is orche-
strated by an upregulation of the chemo-attractant
MCP-1 from microglia.12 Within the CNS, the BM-
DMs interact with microglia to release proinﬂam-
matory cytokines, such as IL-1β and IL-6 within the
parenchyma; these cytokines can disrupt synaptic
plasticity thereby preventing long-term potentiation,
the neurobiologic correlate of learning and mem-
ory.13,14 Resolution of self-limited inﬂammation is
an active process; a combination of vagal activation
that downregulates NFκB by signaling through α7
nicotinic acetylcholine receptors on immunocytes,
and humoral factors especially the SPMs that trans-
duce its signal through G protein-coupled receptors
(GPCRs) which evoke rapid intracellular signaling and
long-term actions by regulating speciﬁc microRNAs
involved in resolution of inﬂammation.15 Together
these neural and humoral processes limit inﬂammation
and restore cognitive function to the pre-morbid
state.16–18
As mentioned above, any proposed pathophysio-
logic mechanism must explain the age-dependency
and the increased risk in certain patient populations
such as metabolic syndrome, and inter-current
infection. Regarding age, it is notable that even at
baseline (i.e. without any intervention) elderly sub-
jects exhibit a low-grade inﬂammatory state that
has been termed ‘inﬂammaging’.19 In an animal
model of the metabolic syndrome, several deﬁcien-
cies in the resolution of inﬂammation following
aseptic trauma were noted.20 To simulate an inter-
current infection, a preclinical model explored the
effect of introducing lipopolysaccharide (LPS), a
constituent of the outer membrane of gram negative
bacteria, to rodents that had undergone aseptic
trauma21; again, excessive inﬂammation and exag-
gerated cognitive decline occurred. A recent meta-
analysis explored the relationship between the
degree of inﬂammation and PND and reported that
levels of both c-reactive protein and IL-6 are
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positively correlated with the prevalence and sever-
ity of PND.22
How does neuroinﬂammation produce
cognitive decline?
This section will focus on the links between hippo-
campal neuroinﬂammation and synaptic and mor-
phological plasticity that are required for successful
learning and memory formation.
Synaptic plasticity
Activated microglia have a profound inﬂuence over
synapse formation/elimination as well as its plasti-
city.23 Apart from the disabling action of pro-
inﬂammatory cytokines on long-term potentiation,24
activated microglia also release reactive oxygen spe-
cies that promote long-term depression.25
Morphological plasticity
The dentate gyrus portion of the hippocampus is
one of only two regions in the mammalian brain
that harbor regenerated neurons into adult life. It is
notable that these neurogenic cells become inte-
grated into hippocampal circuitry; approximately
700 adult-born hippocampal neurones are gener-
ated each day and contribute to its learning and
memory functions.26 Pro-inﬂammatory cytokines,
such as TNF-α, IL-1β and IL-6 interfere with inte-
gration and proliferation of adult hippocampal
neurogenesis27 and thereby prevent the morpho-
logical plasticity required for learning and memory.
Trauma
Cytokines
LTP
disruption 
BM-DMsDAMP
BBB
Chemokines
Neuroinflammation Cognitive Decline
Macrophage interaction
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microglia
activated
microglia
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Fig. 1 A model for perioperative induced neuroinﬂammation and cognitive decline, and possible resolution. High molecular
group Box 1 protein (HMGB1), a damage-associated molecular pattern (DAMP), is passively released from traumatized tissue
during surgery. Through pattern recognition receptors (PRR) on circulating, CCR2-expressing, bone marrow-derived mono-
cytes (BM-DMs), to induce translocation of the transcription factor NFκB into the nucleus where it upregulates the transcrip-
tion and translation of pro-inﬂammatory cytokines. HMGB1 signaling also increases expression of monocyte chemo-attractant
protein-1 (MCP-1) in the central nervous system (CNS) through an unknown mechanism. A cytokine-induced disruption of the
blood–brain barrier (BBB) allows the migration of both cells and potential neurotoxins, such as ﬁbrinogen, into the CNS.
CCR2-expressing BM-DMs, attracted by MCP-1, reach the hippocampus where they transform quiescent microglia, the resi-
dent immunocompetent cells, into its activated form. Together, activated microglia and BM-DMs generate a neuroinﬂamma-
tory response that interferes with long-term potentiation, the synaptic plasticity that is required for learning and memory.
Normal resolution of inﬂammation is an active process that occurs through neural and humoral mechanisms. Neural involves
vagal activation that downregulates NFkB by signaling through α7 nicotinic acetylcholine receptors (α7nAChR) on immuno-
cytes. Regarding humoral factors, the specialized pro-resolving mediator (SPM), Resolvin D1, transduce its signal through
G protein-coupled receptors (GPCRs) which evoke rapid intracellular signaling and long-term actions by regulating pro-
resolving microRNAs (miRNA).
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Preventing neuroinﬂammation
The neuroinﬂammatory response to peripheral sur-
gery appears to be an outmoded teleological defense
mechanism that was probably designed to preserve
animal life in the wild. To wit, if an animal had sus-
tained an injury there needs to be a mechanism miti-
gating further damage and to facilitate the reparative
processes; both the mitigation of further injury and
the repair mechanisms are orchestrated by inﬂamma-
tion, centrally and peripherally, respectively. The
mitigation of further injury appears to be orche-
strated by neuroinﬂammation through the develop-
ment of ‘sickness behavior’ that decreases appetite
and procreative instincts while also producing fever,
cognitive decline and fatigue.28 An animal with the
sickness behavior phenotype is unlikely to forage in the
wild; rather, the injured animal will likely remain in a
cool and non-threatening environment and thereby
keep away from possible predators who can exploit
their injured state.
In the case of aseptic surgical trauma to a hospi-
talized patient, neuroinﬂammation does not appear
to be beneﬁcial for rapid healing. In that context
efforts need to be directed at limiting the neuroin-
ﬂammatory response because of the possible harm
that it can create. Mitigating strategies to prevent
and/or limit neuroinﬂammation can be considered
in three different phases, pre-operatively, intra-
operatively and postoperatively. Also, the strategies
can be designed to affect neuroinﬂammation indir-
ectly (by limiting peripheral inﬂammation) and dir-
ectly on the central inﬂammatory response while
leaving the peripheral inﬂammatory response, and
hence repair of the traumatized site, unhindered.
Preoperative pre-emption of excessive
neuroinﬂammation
Exercise
That aerobic exercise has immune-modulatory
properties was described more than three decades
ago. Healthy young sedentary adult volunteers were
randomized to a 12-week training program at either
moderate or at high intensity which resulted in an
improvement in aerobic capacity. Monocytes were
harvested from peripheral blood and stimulated
with lipopolysaccharide (LPS) and the release of
tumor necrosis factor alpha (TNFα) into the
medium was monitored. The high, but not the mod-
erate, intensity training reduced LPS-induced release
of TNFα into the culture medium.29 These data sug-
gest that immunocytes are re-programmed by exer-
cise although the biologic processes involved were
not identiﬁed.
To explore this ﬁnding further, use was made of
metabolic syndrome rats—referred to as low-
capacity runner (LCR) rats—that were shown to
have an exaggerated and persistent form of post-
operative cognitive decline30 accompanied by an
enhanced inﬂammatory response to the trauma of
surgery.20 The high-capacity runner (HCR) rats did
not exhibit these abnormalities and served as the
controls. The hypothesis was that preoperative
exercise rectiﬁes the abnormal inﬂammatory and
cognitive phenotype following surgery and this was
tested in a preclinical study.31 Each of LCR and
HCR rats was randomly assigned to four groups
and subjected to isoﬂurane anesthesia and tibia
fracture with internal ﬁxation (surgery) or anesthe-
sia alone (sham surgery) and to a preoperative exer-
cise regimen that involved walking for 10 km on a
treadmill over 6 weeks (exercise) or being placed on
a stationary treadmill (no exercise). Cognitive tests
were performed at 3 days as well as 3 months post-
operatively. The previously observed exaggerated
cognitive decline at both time-points was prevented
by preoperative exercise in the LCR rats. Similarly,
preoperative exercise normalized the excessive post-
operative inﬂammation, both systemically and in
the hippocampus. Interestingly, the diversity of the
gut microbiome in the LCR rats improved after
exercise. While the gut microbiome is shown to regu-
late the inﬂammatory response,32 no causality could
be attribute to exercise-induced change in the micro-
biome and improvement in postoperative cognitive
decline. A clinical study (NCT3212300) to determine
whether preoperative exercise decreases the risk for
postoperative cognitive decline is underway.
Nutrition
Analogous to the situation of the metabolic syn-
drome (mentioned above), continuous high-fat diet
5Neuroinﬂammation is a Putative Target for the Prevention and Treatment, 2019
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is associated with a chronic low-grade inﬂamma-
tory state, referred to as meta-inﬂammation; a sec-
ondary response to this systemic inﬂammation is
the activation of microglia.33 A preclinical study
examined the inﬂuence of a western diet on brain
metabolism, transport across the BBB, inﬂammation
and cognitive impairment in a mouse model of
hyperlipidemia.34 The authors reported that a west-
ern diet diminished cognitive processes and was
associated with signiﬁcantly increased BBB perme-
ability as well as microglial Iba1 staining both of
which are indicative of neuroinﬂammation. The
western diet altered the whole mouse brain metabo-
lome that included elevation of the proinﬂamma-
tory lipid mediators.34 Subsequently, it was reported
that a high-fat diet, which induced obesity and insu-
lin resistance, was associated with exaggerated post-
operative cognitive decline and neuroinﬂammation.35
Based upon these studies, investigators have used
dietary manipulation to try to reverse the meta-
inﬂammatory response. In an in vitro experiment,
LPS-induced release of nitric oxide and IL-6 from a
microglial cell line (BV-2 cells) was reduced when the
culture medium included either omega-3 (docosahex-
aenoic and eicosapentaenoic) fatty acids or vitamins
A and D. Moreover, the grouping of vitamins A and
D, together with omega-3 fatty acids, each at concen-
trations where they individually had little effect, com-
bined to signiﬁcantly reduce LPS-induced nitric oxide
release.36 Four-week administration of omega-3 fatty
acids to rats fed a high-fat diet decreased astrogliosis
(GFAP-positive cells in the cerebral cortex) and pro-
inﬂammatory cytokines but not in the hippocam-
pus37; there was no improvement in cognitive decline.
Chunchai et al.38 evaluated the effect of either pre-
biotic (Xylo-oligosaccharide), or probiotic (Lactobacillus
paracasei HII01), or their combination (synbiotics), in
male high-fat diet-induced obese rats. After 12 weeks
of the high-fat diet, gut and systemic inﬂammation
and impaired peripheral insulin sensitivity developed;
these abnormalities were improved by each of the
treatments.38 Prebiotics, probiotics or synbiotics also
improved hippocampal plasticity, attenuated brain
mitochondrial dysfunction, decreased microglial acti-
vation and rectiﬁed cognitive dysfunction.
Based upon these studies, interventions that mod-
ify the preoperative diet may prove to be a viable
strategy for decreasing risk in vulnerable preopera-
tive patients. However, this needs to be tempered by
the underwhelming results from interventional clin-
ical trials with omega-3 fatty acids for a variety of
inﬂammatory conditions.39
Perioperative pre-emption of excessive
neuroinﬂammation
Sleep hygiene
Hospitalized patients are subjected to an environ-
ment that does not facilitate sleep. Zhu et al. inves-
tigated whether sleep deprivation, produced by a
rocker inserted into the mouse cage for 24 h, can
induce neuroinﬂammation and cognitive disturb-
ance tested by Trace Fear Conditioning 1 and 7 days
later.40 Both hippocampal-dependent memory impair-
ment and hippocampal neuroinﬂammation, as evi-
denced by pro-inﬂammatory cytokine IL-6 levels and
microglial activation, were present 24 h after sleep
deprivation and this state persisted for seven days
after sleep deprivation. In a separate study,41 sleep
deprivation was associated with increased levels of
systemic and hippocampal TNF-α, IL-1β, IL-6 and
IL-8 as well as decreased hippocampal and systemic
levels of anti-inﬂammatory cytokines (IL-4; IL-10).
Vacas et al. explored the effects of 24-h pre-surgery
sleep fragmentation in mice.42 While sleep fragmenta-
tion did increase systemic IL-6 and transcription of
TNFα in the hippocampus, it was not associated with a
further deterioration in postoperative cognitive decline.
It is not recommended that benzodiazepines be
used as sleep aids as this class of sedative-hypnotic
does not produce the type of reparative and restora-
tive sleep that is needed to resolve inﬂammation.43
Interestingly, zolpidem, the non-benzodiazepine sleep
aid, beneﬁts patients with a variety of neurological
disorders44; however, zolpidem has not been studied
in the perioperative setting for mitigating PND.
Education
Patients with a higher education level are less prone
to develop dementia although the post-mortem
6 S. Saxena et al., 2019
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examination of the brain did not reveal less neuro-
degenerative changes.45 Higher educational attain-
ment also was associated with less postoperative
decline in a large cohort of elderly surgical patients.6
An ongoing study is investigating whether engaging
in preoperative ‘mental gymnastics’ could prevent
delirium. The mental gymnastics consists of 1 h/day
of electronic tablet-based cognitive exercise for 10
days prior to surgery (NCT02230605).
Reversing neuroinﬂammation
From Fig. 1, it becomes apparent that peripheral
trauma-induced neuroinﬂammation can be addressed
by either focusing interventions on processes in the
periphery or the CNS. For the purposes of this
review no further consideration is given to peripheral
inﬂammatory targets because these are likely to
interfere with wound healing.46 Therefore, in consid-
ering methods of reversing neuroinﬂammation, this
review will focus on the CNS processes that result in
its onset (disruption of the BBB and translocation of
circulating BM-DMs) and its propagation (pro-
inﬂammatory transformation of macrophages).
Restoring the BBB
As disruption of the BBB is a pathognomonic fea-
ture of several acute (e.g. stroke), subacute (neuro-
myelitis optica) and chronic (multiple sclerosis)
neurologic conditions, adoption of successful strat-
egies in these diseases can also be considered in
seeking ways of reducing surgery-induced neuroin-
ﬂammation. Glucocorticosteroids (GC) can reduce
BBB permeability in the setting of multiple scler-
osis47; the mechanism may involve upregulation of
the tight junction proteins claudin and occludin.48
Interestingly, high-dose methylprednisolone was
ineffective in preventing the development of post-
operative delirium after cardiac surgery.49
Mesenchymal stromal cells (MSCs) reside in the
perivascular space and are thought to be progenitors
of pericytes that contribute to the neurovascular
unit that deﬁnes the BBB. Following BBB disruption
in a preclinical model of stroke, administration of
MSCs resulted in increased expression of tight
junction proteins and restoration of the barrier func-
tion.50 Another method of upregulating tight junction
proteins that has been tested in preclinical models is
with laquinimod.51 Also, statins can inhibit isopreny-
lation and also tighten the barrier function in disease
models52; it is notable that a retrospective analysis of
vascular surgery patients suggested that those receiv-
ing preoperative statins had a lower risk for develop-
ing delirium.53 Erythropoietin (EPO) protects brain
endothelium against VEGF-induced permeability by
reducing the level of eNOS and restoring junctional
proteins.54
APOε4 mice have a permeable BBB which can be
reversed by inhibiting the pro-inﬂammatory cyclo-
philin A pathway55; however, inhibitors of cyclophi-
lin A have yet to materialize into the clinical arena.
Also, activated protein C can also improve endothe-
lial barrier integrity56; again, this information has
yet to be translated into clinical utility.
Fibrinogen/ﬁbrin
Increased permeability of the BBB permits inﬂux of
the neurotoxin ﬁbrinogen that is converted to ﬁbrin
through tissue plasminogen activator. Within the
CNS ﬁbrin binds to CD11/CD18 integrin receptor
on tissue macrophages (both microglia and translo-
cated BM-DMs) activating pathways57 that include
nuclear factor-κB (NF-κB), mitogen-activated pro-
tein kinase (MAPK), phosphatidylinositol 3-kinase
(PI3K), AKT (a serine–threonine protein kinase)
and the Rho-family of GTPases. Through the acti-
vation of these pathways the following processes
are affected including adhesion, migration, chemo-
taxis, phagocytosis and transformation into the M1
phenotype; when in the M1 phenotype the brain tis-
sue macrophages release ROS, CCL2 (MCP-1) and
CXCL10 that propagate further trafﬁcking of BM-
DMs, and T lymphocytes into the brain parenchyma.
As ﬁbrinogen/ﬁbrin is necessary and sufﬁcient for the
induction/propagation of neuroinﬂammatory pro-
cesses, this neurotoxin represents a potential target
for reversing neuroinﬂammation.
While there are available compounds that
deplete ﬁbrinogen (ancrod) and promote the
7Neuroinﬂammation is a Putative Target for the Prevention and Treatment, 2019
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degradation of ﬁbrin (tissue plasminogen activator;
tPA), these also can promote severe hemorrhage
because of the key role that ﬁbrinogen/ﬁbrin plays
in the coagulation pathway. Interfering with the
interaction between ﬁbrin and the integrin receptor,
CD11b/CD18, on microglia with a 19 amino acid
residue peptide fragment58 inhibits its activation
(PMID: 17339406). Fibrin can also interact with
β amyloid and this can be prevented with RU 505
which also mitigates the neuroinﬂammation.59 Trials
to test the efﬁcacy of these modulators of ﬁbrin sig-
naling are awaited.
Interrupting macrophage recruitment
The increase in circulating inﬂammatory factors can
disrupt the BBB permitting translocation of CCR2-
expressing BM-DMs into the hippocampus.60 Within
the hippocampus, the tissue macrophages become
activated, synthesize and release pro-inﬂammatory
cytokines that are capable of disrupting long-term
potentiation. Treatment with CCX872, a novel CCR2
selective antagonist, signiﬁcantly reduces TBI-induced
accumulation of inﬂammatory macrophage, multiple
proinﬂammatory and neurotoxic mediators and
hippocampal-dependent cognitive dysfunction.61
Preventing macrophage activation
As microglial activation is a pathognomonic feature
of neuroinﬂammation strategies to prevent its activa-
tion need to be further considered. 18β-Glycyrrhetinic
acid is a major metabolite of glycyrrhizin a constitu-
ent of some traditional Japanese medicines; this
compound has been shown to inhibit microglial
activation in a model of autoimmune encephalomy-
elitis62 and attempts to use this to block liver inﬂam-
mation in clinical trials have not been successful.
There are three major types of K+ channels on
microglia: KV 1.3, Kir 2.1 and KCa 3.1 current. Both
KV 1.3 and KCa 3.1 blockers, PAP-1 and TRAM 34
respectively, inhibit pro-inﬂammatory cytokine pro-
duction and iNOS and COX2 expression demon-
strating that these ion channels play important roles
in microglia activation.63
Transforming macrophage phenotype from
M1 to M2
There are several possible therapeutic candidates
for conversion into the pro-resolving M2 macro-
phage phenotype. Fumarates prevent microglial
activation through a novel hydroxycarboxylic acid
receptor-2 and dampen neuroinﬂammation64; dimethyl
fumarate (Tecﬁdera®), which is biotransformed to the
active monomethyl fumarate, has been shown to be
clinically useful in MS patients and is available for fur-
ther exploration in other clinical settings including
PND. JWH133, a selective cannabinoid receptor-2
(CB2) agonist, suppresses neuroinﬂammation by
modulating microglial polarization to the M2
phenotype through activation of the protein kinase
A (PKA) pathway.65 As other cannabinoids (CB1
agonists) are progressing through clinical trials it is
possible that selective CB2 agonists may also become
available for conditions such as PND. Acting via the
PGC-1α pathway, resveratrol promotes the convers-
tion of microglia to the M2 phenotype; importantly,
resveratrol attenuated both LPS-induced neuroin-
ﬂammation and sickness behavior.66 Two recently
completed, but as yet unreported, clinical trials have
explored the clinical potential of resveratrol in the
setting of cognitive decline; a positive demonstration
of its efﬁcacy vs cognitive decline may result in
extension to PND.
Conclusion
Current evidence strongly supports targeting neuroin-
ﬂammation for the prevention and reversal of peri-
operative neurocognitive disorders. Extrapolating
from other neurological disorders, such as multiple
sclerosis and Alzheimer’s Disease in which neuroin-
ﬂammation plays a prominent role, there are several
possible interventions both pharmacological and
non-pharmacological. Clinical trials are needed to
test the efﬁcacy and safety of these interventions.
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